Incyte Corporation (INCY) is a biopharmaceutical company with a market cap of $20.9 billion, focused on innovative therapeutics in oncology, immunology, and dermatology.

Analysts expect INCY to report a profit of $1.66 per share in Q4 2025, a 52.3% increase from the year-ago quarter and forecast EPS of $5.86 for fiscal 2025.

INCY stock has surged 50.7% in the past 52 weeks, surpassing the S&P 500 and XLV returns, and reported strong Q3 2025 results with revenue of $1.37 billion.

Analysts rate INCY stock as cautiously optimistic, with a “Moderate Buy” overall, with 12 “Strong Buy,” 12 “Holds,” and one “Strong Sell” ratings out of 25 analysts covering the stock.

Read more at Yahoo Finance: What To Expect From Incyte’s Report